Zhaoke Says Novel Dry Eye Treatment Hits Endpoint in Phase III Trial
publication date: Aug 20, 2021
Zhaoke Ophthalmology of Guangzhou said its dry eye disease treatment met the primary endpoint in a China Phase III trial. Cyclosporine A (CsA) Ophthalmic Gel is administered once daily, as opposed to the twice-daily dosing of competing products. CsA is a proprietary hydrogel designed to stay on the cell surface longer, improving efficacy. In the Phase III trial, CsA showed a significant improvement in the inferior fluorescein corneal staining score. Zhaoke, an indirect non-wholly-owned subsidiary of Lee's Pharm, develops Lee's portfolio of in-licensed ophthalmology drugs. More details....
Stock Symbols: (HK: 6622) (HK: 0950)
Share this with colleagues:
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.